This Biotech Stock Soars 47% Amidst Massive $10M Direct Offering
Vaxart Shares Soar 47% Following $10M Direct Offering with RA Capital Management.
Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
In an exciting turn of events, shares of biotechnology company Vaxart Inc. (NASDAQ: VXRT) rocketed up by an impressive 47% to close at $0.8250 on Wednesday. The surge in stock price followed the company's announcement of a $10 million registered direct offering with RA Capital Management. The news, which has significant implications for investors, was initially disclosed in a press release by Vaxart on Tuesday.
The deal with RA Capital Management, a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies, is expected to close on or about January 21, 2024, subject to customary closing conditions.
Under the terms of the securities purchase agreement, Vaxart will sell approximately 12.1 million shares of its common stock at a purchase price of $0.825 per share, which equals the closing price of Vaxart's common stock on January 17, 2024.
The proceeds from this direct offering will be used for general corporate purposes, including the continuation and expansion of product manufacturing, the progression of Vaxart's product pipeline, and for general and administrative expenses.
This move signifies a vote of confidence in Vaxart's potential from RA Capital Management, a reputable institutional investor with a track record of successful investments in the healthcare sector.
It is important for investors to understand the potential risks involved in such an investment. While the surge in Vaxart's stock price is promising, it is also crucial to consider the volatile nature of the stock market and the inherent uncertainties involved in biotechnology research and development.
Nevertheless, this significant financial boost could pave the way for Vaxart to further its research and development efforts, potentially leading to groundbreaking advancements in the field of oral vaccines.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources: